Kun Liu

Dr. Kun Liu

orcid

Research Focus & Metrics

Representative Publications

View All Publications
3 August 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
KLKun Liu
Kun Liu
SHShengyuan He
Shengyuan He
SSShangqin Sun
Shangqin Sun
XZXinxin Zhang
Xinxin Zhang
YHYanzhen He
Yanzhen He
YXYun Xiao
Yun Xiao
The remarkable success of cancer immunotherapy has revolutionized cancer treatment, emphasizing the importance of tumor–immune interactions in cancer evolution and treatment. Cancer immunoediting describes the dual effect of tumor–immune interactions: inhibiting tumor growth by destroying tumor cells and facilitating tumor escape by shaping tumor immunogenicity. To better understand tumor–immune interactions, it is critical to develop computational methods to measure the extent of cancer immunoediting. In this review, we provide a comprehensive overview of the computational methods for quantifying cancer immunoediting. We focus on describing the basic ideas, computational processes, advantages, limitations, and influential factors. We also summarize recent advances in quantifying cancer immunoediting studies and highlight future research directions. As the methods for quantifying cancer immunoediting are continuously improved, future research will further help define the role of immunity in tumorigenesis and hopefully provide a basis for the design of new personalized cancer immunotherapy strategies.

16 January 2026 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
LDLantian Deng
Lantian Deng
WLWei Liu
Wei Liu
JXJinyuan Xu
Jinyuan Xu
BZBo Zhang
Bo Zhang
SHShengyuan He
Shengyuan He
YXYun Xiao
Yun Xiao
Single-cell studies have significantly advanced our understanding of the transcriptional and functional heterogeneity in cancers. Recent studies have identified distinct states of cancer, immune, and stromal cells in the tumor microenvironment (TME), with growing evidence highlighting their clinical significance and therapeutic potential. Here, we present CancerSEA-X, an expanded version of CancerSEA that offers a comprehensive atlas of TME cell states. CancerSEA-X integrates 25 cancer cell states, 105 immune cell states, and 26 stromal cell states from systematically curated publications. Combining 239 single-cell datasets across 32 cancer types, encompassing over 9 million cells from 2120 patients, CancerSEA-X provides functional activity spectra and cancer-specific gene associations for these 156 cell states. These cell state-gene relationships were mapped onto networks, providing a systematic view of the TME. To improve usability, we redesigned the user interface to feature cell state characterization, state-gene correlation analysis, and interactive visualization of cell state-gene networks, enabling researchers to comprehensively explore these states and their functional relevance. Overall, CancerSEA-X serves as a valuable platform for investigating TME cell states, deepening our understanding of cancer heterogeneity, and potentially advancing the design of more effective clinical therapies. CancerSEA-X is freely available at http://biocc.hrbmu.edu.cn/CancerState.

Verified
Journal Article
Open access
PDF file
KLKun Liu
Kun Liu
XLXinyu Liu
Xinyu Liu
LDLantian Deng
Lantian Deng
YLYu Liu
Yu Liu
QFQuan Fei
Quan Fei
YXYun Xiao
Yun Xiao
Geographic variation in colorectal cancer (CRC) incidence and mutational spectra has been well described, whereas the extent to which regional context is associated with tumor evolutionary timing remains unclear. We first examined the association between CRC incidence and mean annual temperature and then analyzed whole-exome sequencing data from 688 microsatellite-stable (MSS) CRCs across four Chinese cohorts, classifying tumors from Harbin and Beijing (n = 65) as the cold-region group and those from Guangzhou (n = 623) as the non-cold-region group. Comparative analyses revealed differences in mutational processes and evolutionary timing between the two groups. Specifically, cold-region tumors exhibited higher estimated contributions from mutational signature SBS93, a more polarized distribution of copy-number gain timing, and later inferred molecular timing of whole-genome doubling. Patients in the cold-region group were also diagnosed at younger ages, and higher SBS93 exposure was associated with younger age at diagnosis. In contrast, no widespread differences were detected in driver gene mutation frequencies, copy-number alterations, genomic instability metrics, or most immune-related features. Together, these findings suggest distinct mutational processes and evolutionary timing patterns in MSS CRCs from cold-region and non-cold-region cohorts, providing new insights into the geographic heterogeneity of colorectal cancer evolution.